{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:41:55Z","timestamp":1777556515793,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Serum C-peptide concentration is often utilized for diagnostic, prognostic, or therapeutic assessment in diabetes mellitus. However, there are limited clinical data regarding diagnostic and predictive value of C-peptide measured during hospitalizations for hyperglycemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Adults admitted to Mayo Clinic inpatient facilities due to an acute hyperglycemic emergency between January 2017 and November 2022 were included in our study. Predictive capacity of C-peptide for discontinuation of therapeutic insulin was examined in the entire cohort and the subgroup of non-autoimmune non-pancreatitis diabetes (NANP-DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We included 187 patients (63 women) in our study. During hospitalization, patients with type 1 diabetes antibodies displayed diminished serum C-peptide concentration (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014), correlating inversely with subsequent hemoglobin A1c% [\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      = (\u22120.22),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005]. Initial C-peptide concentrations did not differ between patients requiring insulin therapy during follow-up and those who did not (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.16). C-peptide concentrations showed limited predictive capacity for achieving glycemic control. Subgroup analyses in NANP-DM exhibited similar limited capacity for anticipating therapeutic insulin needs and achieving glycemic controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>C-peptide concentration did not exhibit a robust predictive capability for future need of insulin therapy and achieving glycemic control, limiting its utility in clinical practice within inpatient settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2024.0246","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T17:08:36Z","timestamp":1725383316000},"page":"121-127","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Utility of Serum C-Peptide Concentration for Hospitalized Patients with Hyperglycemia"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-5134","authenticated-orcid":false,"given":"Damla N.","family":"Costa","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-6622","authenticated-orcid":false,"given":"Yogish C.","family":"Kudva","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, Minnesota, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(84)90128-8"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12850"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13960"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01418-z"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S426956"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.k10e-399"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.k09e-279"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14129"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.4137"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15595"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.125"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13142"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.01.004"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14449"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00975.x"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0749"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.5.6.305"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.4.2.82"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108667"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06067-3"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134057"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13426"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0244"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2024.0246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2024.0246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2024.0246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:14:58Z","timestamp":1777400098000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2024.0246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1089\/dia.2024.0246"],"URL":"https:\/\/doi.org\/10.1089\/dia.2024.0246","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}